<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192335</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP112</org_study_id>
    <nct_id>NCT00192335</nct_id>
  </id_info>
  <brief_title>Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants</brief_title>
  <official_title>A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      -  Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist&#xD;
&#xD;
        -  Secondary objective of this study is to assess the safety and tolerability of CAIV-T&#xD;
           compared to FluMist&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Among participants 5 through 8 years of age regardless of baseline serostatus who receive two doses, the post-dose two strain-specific geometric mean titers (GMTs) for serum HAI in the CAIV-T group are within 2-fold of those in the FluMist group</measure>
    <time_frame>greater than 28-days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants experiencing each of the reactogenicity events by dose.</measure>
    <time_frame>Within 28 days of vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">890</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIVT</intervention_name>
    <description>The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist</intervention_name>
    <description>The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 5 through 49 years (not yet reached their 50th birthday);&#xD;
&#xD;
          -  In general good health;&#xD;
&#xD;
          -  Individual or parent/guardian available by telephone;&#xD;
&#xD;
          -  Ability of the participant or parent/guardian to understand and comply with the&#xD;
             requirements of the protocol; and&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization obtained from the participant's&#xD;
             parent or legal guardian or written informed consent and HIPAA authorization obtained&#xD;
             from the participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any component of FluMist or CAIV-T, including egg or&#xD;
             egg products;&#xD;
&#xD;
          -  History of hypersensitivity to gentamicin;&#xD;
&#xD;
          -  Any known immunosuppressive condition or immune deficiency disease (including HIV&#xD;
             infection), or ongoing receipt of any immunosuppressive therapy;&#xD;
&#xD;
          -  Household contact who is immunocompromised (participants should also avoid close&#xD;
             contact with other immunocompromised individuals for at least 21 days);&#xD;
&#xD;
          -  History of chronic underlying medical conditions such as chronic disorders of the&#xD;
             cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes),&#xD;
             renal dysfunction, or hemoglobinopathies;&#xD;
&#xD;
          -  History of Guillain-Barré syndrome;&#xD;
&#xD;
          -  History of asthma or reactive airways disease;&#xD;
&#xD;
          -  For children age 5 through 8 years, receipt of prior influenza vaccination;&#xD;
&#xD;
          -  Acute febrile (&gt;100.0°F oral) and/or respiratory illness within the 72 hours prior to&#xD;
             enrollment;&#xD;
&#xD;
          -  For participants under the age of 18, use of aspirin or aspirin containing products in&#xD;
             the 30 days prior to enrollment or anticipated use during the study;&#xD;
&#xD;
          -  Administration of any live vaccine within 30 days prior to enrollment or if receipt of&#xD;
             another live vaccine is expected within 30 days of the vaccination in this study;&#xD;
&#xD;
          -  Administration of any inactivated vaccine within two weeks prior to enrollment or if&#xD;
             receipt of another inactivated vaccine is expected within two weeks of the vaccination&#xD;
             in this study;&#xD;
&#xD;
          -  Pregnancy or, in biologically capable women (e.g., menses within the last year), not&#xD;
             willing to agree to acceptable birth control for 90 days after enrolling into the&#xD;
             study (for those biologically capable, a urine pregnancy test must be performed on the&#xD;
             day of vaccination with a negative result);&#xD;
&#xD;
          -  Breastfeeding or lactating women;&#xD;
&#xD;
          -  Participation in another investigational trial or administration of any&#xD;
             investigational drug within 30 days prior to enrollment or during this study;&#xD;
&#xD;
          -  Receipt of any blood product within 90 days prior to vaccination or expected receipt&#xD;
             within the study duration;&#xD;
&#xD;
          -  Employees of the research center, any individuals involved with the conduct of the&#xD;
             study, or any family member of such individuals; and&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would interfere with the&#xD;
             interpretation or evaluation of the vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Angles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart of America Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart of America Research Institute</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research, Inc.</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R/D Clinical Research, Inc.</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

